Ken Griffin Capricor Therapeutics, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$3.56 - $15.21 $410,112 - $1.75 Million	115,200 Added 313.9%	151,900 $2.31 Million
Q2 2024 Aug 14, 2024	BUY	$4.63 - $7.09 $63,894 - $97,842	13,800 Added 60.26%	36,700 $175,000
Q1 2024 May 15, 2024	BUY	$3.61 - $6.88 $30,685 - $58,480	8,500 Added 59.03%	22,900 $155,000
Q4 2023 Feb 14, 2024	SELL	$2.71 - $5.08 $26,287 - $49,276	-9,700 Reduced 40.25%	14,400 $70,000
Q3 2023 Nov 14, 2023	BUY	$3.42 - $7.85 $58,482 - $134,235	17,100 Added 244.29%	24,100 $82,000
Q2 2023 Aug 14, 2023	SELL	$3.76 - $5.05 $122,576 - $164,630	-32,600 Reduced 82.32%	7,000 $33,000
Q1 2023 May 15, 2023	SELL	$3.78 - $5.03 $390,096 - $519,096	-103,200 Reduced 72.27%	39,600 $167,000
Q4 2022 Feb 14, 2023	SELL	$3.36 - $6.55 $1,680 - $3,275	-500 Reduced 0.35%	142,800 $551,000
Q3 2022 Nov 14, 2022	BUY	$3.61 - $6.08 $308,655 - $519,840	85,500 Added 147.92%	143,300 $860,000

8.13M

1.78M

1.4M

Ticker CAPR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,346,200
Market Cap $465M
Description
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for th...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.